Both lead compounds exerted potent activity (GI50 value) against highly SGPL1-expressing RMG-I ovarian carcinoma cell but not poorly SGPL1expressing ES-2 cells (Fig. 1b,c, Tables 1 and 2). This evidence concerns the gene SGPL1 and ovarian carcinoma.